ATE489950T1 - Lösung enthaltend n-acetylcystein und gluconsäure,und verfahren zur verringerung, behandlung und/oder verhinderung von oxidativem stress und zellaktivierung - Google Patents

Lösung enthaltend n-acetylcystein und gluconsäure,und verfahren zur verringerung, behandlung und/oder verhinderung von oxidativem stress und zellaktivierung

Info

Publication number
ATE489950T1
ATE489950T1 AT07764759T AT07764759T ATE489950T1 AT E489950 T1 ATE489950 T1 AT E489950T1 AT 07764759 T AT07764759 T AT 07764759T AT 07764759 T AT07764759 T AT 07764759T AT E489950 T1 ATE489950 T1 AT E489950T1
Authority
AT
Austria
Prior art keywords
solution
cell activation
oxidative stress
gluconic acid
acetylcystein
Prior art date
Application number
AT07764759T
Other languages
English (en)
Inventor
Reinhold Deppisch
Werner Beck
Andrea Schnell
Hans-Rainer Drieschmanns
Original Assignee
Gambro Lundia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gambro Lundia Ab filed Critical Gambro Lundia Ab
Application granted granted Critical
Publication of ATE489950T1 publication Critical patent/ATE489950T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07764759T 2006-06-22 2007-06-21 Lösung enthaltend n-acetylcystein und gluconsäure,und verfahren zur verringerung, behandlung und/oder verhinderung von oxidativem stress und zellaktivierung ATE489950T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80548906P 2006-06-22 2006-06-22
PCT/EP2007/005466 WO2007147590A2 (en) 2006-06-22 2007-06-21 Solution and method to reduce, treat and/or prevent oxidative stress and cell activation

Publications (1)

Publication Number Publication Date
ATE489950T1 true ATE489950T1 (de) 2010-12-15

Family

ID=38614318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07764759T ATE489950T1 (de) 2006-06-22 2007-06-21 Lösung enthaltend n-acetylcystein und gluconsäure,und verfahren zur verringerung, behandlung und/oder verhinderung von oxidativem stress und zellaktivierung

Country Status (8)

Country Link
US (1) US20100204328A1 (de)
EP (1) EP2040689B1 (de)
AT (1) ATE489950T1 (de)
CA (1) CA2655644C (de)
DE (1) DE602007010938D1 (de)
ES (1) ES2355853T3 (de)
PL (1) PL2040689T3 (de)
WO (1) WO2007147590A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010112547A1 (en) * 2009-03-31 2010-10-07 Gambro Lundia Ab Dialysis precursor composition
AU2016310538B2 (en) 2015-08-24 2022-04-07 Vitrolife Sweden Ab Culture medium
RU2709501C1 (ru) * 2019-10-15 2019-12-18 Виктор Александрович Сисев Фармацевтическая композиция для парентерального капельного введения

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158487B1 (de) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stabile Interleukin-2-Zusammensetzung
JP3714689B2 (ja) * 1994-10-27 2005-11-09 ユニチカ株式会社 ビリルビン測定用試薬
US5871769A (en) * 1996-01-18 1999-02-16 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of diabetes mellitus
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
PT1062879E (pt) * 1999-06-26 2003-12-31 Braun Melsungen Ag Solucao aquosa para nutricao parenteral
KR100390630B1 (ko) * 1999-07-02 2003-07-07 이희발 항 산화제를 함유한 복막투석액
AU7879500A (en) * 1999-10-15 2001-04-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
US7014990B2 (en) * 2000-10-13 2006-03-21 Ben O'Mar Arrington Machine perfusion solution for organ and biological tissue preservation
AU2002356953A1 (en) * 2001-11-16 2004-06-03 Beatrice M. Klysz Anti-aging skin care composition and uses thereof
JP4894219B2 (ja) * 2004-10-15 2012-03-14 ニプロ株式会社 ビタミンｂ群配合末梢静脈栄養輸液
EP1951337B1 (de) * 2005-10-17 2018-08-01 Gambro Lundia AB Extrakorporale blutreinigung

Also Published As

Publication number Publication date
WO2007147590A3 (en) 2008-03-13
WO2007147590A2 (en) 2007-12-27
EP2040689B1 (de) 2010-12-01
ES2355853T3 (es) 2011-03-31
EP2040689A2 (de) 2009-04-01
CA2655644A1 (en) 2007-12-27
CA2655644C (en) 2013-01-08
PL2040689T3 (pl) 2011-04-29
DE602007010938D1 (de) 2011-01-13
US20100204328A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
EP4233861A3 (de) Zusammensetzungen zur behandlung von essentiellem tremor
EA201490913A1 (ru) Лекарственные формы для лечения сахарного диабета
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
TW200503751A (en) Methods for treating sinus headache
EA201390482A1 (ru) Повышающий вязкость агент для регулирования водоотдачи с использованием хелатов
EA201001749A1 (ru) Способ лечения недифференцированного артрита
MX392388B (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe)
ATE500319T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
DE602006020867D1 (de) Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
RU2015111255A (ru) Экспрессия химерного белка ksac и способ получения растворимых белков с помощью высокого давления
EA201290278A1 (ru) Способ лечения сердечной недостаточности с использованием стресскопинподобных пептидов
EA201691420A1 (ru) Композиции енолазы 1 (eno1) и их применение
BR112013022414A2 (pt) método para melhorar a rejeição de membrana permeável, agente de tratamento para melhorar a rejeição e membrana permeável
DE602006017654D1 (de) Filterungssystem zur herstellung von flüssigkeiten für medizinische anwendungen
ATE489950T1 (de) Lösung enthaltend n-acetylcystein und gluconsäure,und verfahren zur verringerung, behandlung und/oder verhinderung von oxidativem stress und zellaktivierung
DK1973541T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater til nedsættelse af lipid- og blodglucoseniveauer
NO20075695L (no) Fremgangsmate til a behandle eller forhindre type-2 diabetes
EP2106260A4 (de) Insulin-sensibilisatoren und behandlungsverfahren damit
DE602005003836D1 (de) Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas
RU2007103435A (ru) Способ патогенетического лечения клещевых нейроинфекций
GB2583667A8 (en) Device for selective removal of molecules from tissues or fluids
Bushell et al. Dihydrolipoic acid improves diabetic endothelial cell function via the H2S‐producing enzyme 3‐mercaptopyruvate sulfurtransferase
RU2013151040A (ru) Способ лечения хронического аденоидита у детей

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties